GlaxoSmithKline Pharmaceuticals share price
NSE: GLAXOBSE: 500660Pharmaceuticals & BiotechnologyMid Cap
Share price at the NSE close on 23 Oct 2026. Previous close ₹2,433.70.
- Next results date: the board meets on 3 Nov 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹40,737 Cr221st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 3 Aug 2026
- 38.1
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 13 May 2026
- 18.0
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 2.37%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 3 Aug 2026
- 50.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 3 Aug 2026
- 56.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 13 May 2026
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 56,17458.6% delivered
Results
Consolidated; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 3 Aug
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹938 Crdown 5.71%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹237 Crdown 14.64%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 25.3%
Revenue by year
Net profit by year, a loss in red
The years either side of a change of basis do not compare. From the year to Mar 2022, the company's revenue for that year, ₹3,278 Cr, differs from its quarters added, ₹3,425 Cr; the company reports a discontinued business.
| ₹ crore | Sep 2024Filed 31 Oct | Dec 2024Filed 14 Feb | Mar 2025Filed 12 Jun | Jun 2025Filed 1 Aug | Sep 2025Filed 6 Nov | Dec 2025Filed 9 Feb | Mar 2026Filed 13 May | Jun 2026Filed 3 Aug |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,011 | 949 | 974 | 805 | 980 | 1,041 | 995 | 938 |
| Net profit | 253 | 230 | 263 | 205 | 257 | 296 | 278 | 237 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 25.0% | 24.2% | 27.0% | 25.5% | 26.3% | 28.4% | 27.9% | 25.3% |
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceuticals, which carries all its revenue.
Valuation
Today, against the company's own history. Its history crosses a change of basis in the accounts in the year to Mar 2022: days before it are of the company before the change.PE ratio and valuation history
At or below today's level on 2% of 2,412 trading days over the last 10 years.
At or below today's level on 51% of 1,984 trading days since Oct 2018.
At or below today's level on 18% of 1,912 trading days since Feb 2019.
At or below today's level on 79% of 2,475 trading days over the last 10 years.
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −18.2% | +11.7% | −29.0% | 2.5% |
| 3 years | +21.9% | +19.3% | +0.5% | 2.0% |
| 5 years | +12.4% | +23.7% | −11.3% | 2.8% |
Mutual funds holding it
137 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 71 of the 83 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future. 2 more funds filed their first portfolio on record, holding it.Mutual fund holdings
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 2
- Bought againBought again. Funds that held it at the month's end, had not held it the month before, and held it in an earlier month.
- 1
- AddedAdded. Funds that held more shares than at the end of the month before.
- 40
- CutCut. Funds that held fewer shares than at the end of the month before.
- 43
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 49
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end.
- 1
| Fund | |||
|---|---|---|---|
 SBI Midcap FundSBI Mutual Fund | 11,80,000 | 1.40% | ₹326.8 Cr |
 Kotak Large & Mid Cap FundKotak Mahindra Mutual Fund | 11,00,000 | 1.00% | ₹304.6 Cr |
 Nippon India Pharma FundNippon India Mutual Fund | 10,29,460 | 3.11% | ₹285.1 Cr |
 quant Mid Cap Fundquant Mutual Fund | 8,89,486 | 3.22% | ₹246.3 Cr |
| Nippon India Growth Mid Cap FundNippon India Mutual Fund | 5,59,000 | 0.31% | ₹154.8 Cr |
| SBI Dividend Yield FundSBI Mutual Fund | 4,50,000 | 1.55% | ₹124.6 Cr |
 Bandhan Large & Mid Cap FundBandhan Mutual Fund | 3,47,860 | 0.47% | ₹96.3 Cr |
 Bajaj Finserv Flexi Cap FundBajaj Finserv Mutual Fund | 3,35,705 | 1.09% | ₹93.0 Cr |
| Bandhan ELSS - Tax Saver FundBandhan Mutual Fund | 2,75,000 | 1.15% | ₹76.2 Cr |
 Tata Aggressive Hybrid FundTata Mutual Fund | 2,50,000 | 1.74% | ₹69.2 Cr |
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to GlaxoSmithKline Pharmaceuticals in market cap.
Where the company sits among the companies nearest its size
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 BioconBIOCON | 52,721 | 106.4 | 1.5 | 18.2 | +9.8% | +28.6% | 1.8% | 2.9% | 0.15% |
 IPCA LaboratoriesIPCALAB | 49,556 | 37.8 | 6.1 | 22.3 | +10.6% | +68.2% | 17.4% | 17.6% | 0.31% |
 Gland PharmaGLAND | 46,645 | 41.3 | 4.5 | 24.9 | +17.6% | +46.5% | 11.6% | 12.4% | 0.71% |
 Ajanta PharmaAJANTPHARM | 41,035 | 36.2 | 9.1 | 28.0 | +20.2% | +22.0% | 27.3% | 27.2% | 1.83% |
 Emcure PharmaceuticalsEMCURE | 33,586 | 33.2 | 6.8 | 17.5 | +18.4% | +35.9% | 21.5% | 25.2% | 0.20% |
 Sai Life SciencesSAILIFE | 29,639 | 81.9 | 11.9 | 45.0 | – | – | 15.7% | 18.7% | 0.00% |
 WockhardtWOCKPHARMA | 29,276 | 71.6 | 5.9 | 40.4 | +18.4% | – | 8.8% | 7.4% | 0.00% |
 Acutaas ChemicalsACUTAAS | 25,689 | 66.5 | 15.5 | 47.0 | +40.9% | +104.3% | 26.1% | 29.1% | 0.08% |
Dividends
Per share, by the year it was paid for, and the latest payments.Dividend history and dates
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up.| Ex-date | Type | Per share |
|---|---|---|
| 29 May 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹57.00 |
| 30 May 2025 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹42.00 |
| 7 Nov 2024 | Interim | ₹12.00 |
| 31 May 2024 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹32.00 |
| 30 Jun 2023 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹32.00 |
| 7 Jul 2022 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹30.00 |
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
13 Oct · Updates
Sep 2026
2 Sep · Meeting
Aug 2026
26 Aug · Volume Movement Letter
GlaxoSmithKline Pharmaceuticals share price by year
Each calendar year to 2025.GlaxoSmithKline Pharmaceuticals share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 2,473.60 | +9.8% | 3,466.20 | 1,956.20 |
| 2024 | 2,251.85 | +18.6% | 3,061.45 | 1,871.20 |
| 2023 | 1,898.15 | +43.9% | 1,898.15 | 1,230.60 |
| 2022 | 1,318.75 | −24.9% | 1,773.75 | 1,300.45 |
| 2021 | 1,756.65 | +8.2% | 1,882.60 | 1,401.55 |
| 2020 | 1,623.95 | +0.8% | 1,778.60 | 1,101.85 |
| 2019 | 1,610.30 | +6.3% | 1,697.65 | 1,140.05 |
| 2018 | 1,515.35 | +21.7% | 1,795.05 | 1,043.88 |
| 2017 | 1,244.65 | −8.8% | 1,380.60 | 1,165.28 |
| 2016 | 1,364.90 | −17.6% | 1,907.38 | 1,305.05 |
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | 2,432.80 | 2,432.80 | 2,344.10 | 2,404.70 | 2,390.68 | 56,174 | 58.6% |
| 22 Oct 2026 | 2,460.00 | 2,464.60 | 2,422.20 | 2,433.70 | 2,436.82 | 22,943 | 52.2% |
| 21 Oct 2026 | 2,460.00 | 2,517.90 | 2,445.00 | 2,464.40 | 2,470.00 | 27,689 | 44.6% |
| 19 Oct 2026 | 2,555.10 | 2,555.20 | 2,473.30 | 2,495.40 | 2,502.72 | 21,147 | 51.8% |
| 16 Oct 2026 | 2,530.00 | 2,573.20 | 2,518.40 | 2,566.10 | 2,556.74 | 61,686 | 54.7% |
| 15 Oct 2026 | 2,538.00 | 2,538.00 | 2,491.20 | 2,524.70 | 2,515.95 | 45,439 | 57.2% |
| 14 Oct 2026 | 2,536.30 | 2,548.30 | 2,502.00 | 2,538.90 | 2,527.86 | 41,627 | 44.1% |
| 13 Oct 2026 | 2,525.10 | 2,545.00 | 2,495.00 | 2,536.30 | 2,522.15 | 31,087 | 45.1% |
| 12 Oct 2026 | 2,530.10 | 2,555.80 | 2,520.10 | 2,531.50 | 2,538.45 | 28,359 | 39.4% |
| 9 Oct 2026 | 2,534.40 | 2,565.00 | 2,485.00 | 2,540.30 | 2,534.51 | 41,351 | 38.1% |
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Bonus share history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 11 Sep 2018 | Bonus | 0.5000 | Holders received 1 bonus share for every 1 held. |
About GlaxoSmithKline Pharmaceuticals
GlaxoSmithKline Pharmaceuticals Limited makes and sells medicines and vaccines in India. It is the Indian subsidiary of GSK plc, a UK-based healthcare company, and its headquarters are in the Worli area of Mumbai. Its registered office is at GSK House, Dr. Annie Besant Road.
The business is organised into three portfolios: General Medicines, Vaccines and Specialty Medicines. General Medicines covers anti-infectives, pain management, dermatological products, hormones, and vitamins, minerals and nutritional products. Vaccines covers adult and paediatric vaccines. Specialty Medicines covers respiratory care and oncology, a segment the company entered in 2025. Its brands include Augmentin, Calpol and Betnovate in General Medicines, Shingrix and Havrix in Vaccines, and Nucala and Jemperli in Specialty Medicines.
The company manufactures oral solid dosage and dermatology products at its plant in Ambad, Nashik, Maharashtra. A Global Capability Centre in Bengaluru, set up by GSK plc in 2021, brings together teams that support global business operations, enterprise functions and pharmaceutical research and development.
It was incorporated in 1924 and has been listed in India since 1969.
The company belongs to the GSK plc group. Its promoter group includes Glaxo Group Limited, U.K., GlaxoSmithKline Pte Limited, Singapore, Eskaylab Limited, U.K. and Burroughs Wellcome International Limited, U.K. A promoter is the person or group that set up a company or controls it. Together, these four shareholders hold 75.00% of the paid-up share capital.
- Legal name
- GlaxoSmithKline Pharmaceuticals Limited
- NSE symbol
- GLAXO
- BSE code
- 500660
- ISIN
- INE159A01016
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Jan 1969 on BSE, Dec 2000 on NSE
- Face value
- ₹10
- CIN
- L24239MH1924PLC001151
- Corporate identity number, the registrar of companies' code for it